For Your Information
FTC Approves Final Order Preserving Competition in the U.S. Markets for Generic Drugs to Treat Certain Types of Ulcers, and Thyroid Conditions
Following a public comment period, the Federal Trade Commission has approved a final order settling charges that the $8 billion merger between Endo International plc and Par Pharmaceuticals, Inc. would likely be anticompetitive.
Under the order, first announced in September 2015, the companies are required to sell Endo’s U.S. rights and assets for generic glycopyrrolate tablets, which are used with other drugs to treat certain types of ulcers, and generic methimazole tablets, which are used to treat the body’s production of excess thyroid hormone to Rising Pharmaceuticals.
The Commission vote approving the final order was 4-0. (FTC File No. 151 0137; the staff contact is Stephanie C. Bovee, Bureau of Competition, 202-326-2083)
The Federal Trade Commission works to promote competition, and to protect and educate consumers. The FTC will never demand money, make threats, tell you to transfer money, or promise you a prize. You can learn more about how competition benefits consumers, file an antitrust complaint, or comment on a proposed merger. For the latest news and resources, follow the FTC on social media, subscribe to press releases, and read our blog.
Contact Information
MEDIA CONTACT:
Betsy Lordan
Office of Public Affairs
202-326-3707